SCHEMBL15218642

SCHEMBL15218642

Cc1ccc(/C=C/C(=O)c2ccc(O)cc2O)cc1C

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.72
KMT2A Q03164 6/20 0.72
CYP3A4 P08684 5/20 0.72
NFKB1 P19838 4/20 0.72
TDP1 Q9NUW8 4/20 0.72
MAPT P10636 4/20 0.72
HPGD P15428 4/20 0.72
ALOX15 P16050 4/20 0.72
MAPK1 P28482 4/20 0.72
NFKB2 Q00653 3/20 0.72
RELA Q04206 3/20 0.72
TP53 P04637 3/20 0.72
HSD17B10 Q99714 3/20 0.72
CYP2C9 P11712 2/20 0.72
CYP2C19 P33261 2/20 0.72
AKR1B1 P15121 2/20 0.72
HSD17B2 P37059 2/20 0.72
LMNA P02545 2/20 0.72
GMNN O75496 1/20 0.72
ESR1 P03372 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31232994 1.00 MEN1 (0.72) MEN1KMT2ACYP3A4NFKB1TDP1
SCHEMBL17356221 0.91 MEN1 (0.76) MEN1KMT2ACYP3A4NFKB1TDP1
SCHEMBL30382794 0.91 MEN1 (0.76) MEN1KMT2ACYP3A4NFKB1TDP1
SCHEMBL30383541 0.91 MEN1 (0.76) MEN1KMT2ACYP3A4NFKB1TDP1
SCHEMBL17616945 0.91 MEN1 (0.76) MEN1KMT2ACYP3A4NFKB1TDP1
SCHEMBL14491082 0.87 MEN1 (0.69) MEN1KMT2ACYP3A4NFKB1TDP1
SCHEMBL25208375 0.86 MEN1 (0.96) MEN1KMT2ACYP3A4NFKB1TDP1
SCHEMBL12021254 0.85 MEN1 (0.81) MEN1KMT2ACYP3A4NFKB1TDP1
SCHEMBL30384411 0.85 MEN1 (0.81) MEN1KMT2ACYP3A4NFKB1TDP1
SCHEMBL13084333 0.85 MEN1 (0.82) MEN1KMT2ACYP3A4NFKB1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
EP-4429763-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS Yewsavin, Inc. (US) 2024-09-18 EP disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed
US-20160193126-A1 DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES UNIGEN INC (US) 2016-07-07 US disclosed
US-9126913-B2 Diarylalkanes as potent inhibitors of binuclear enzymes UNIGEN, INC. (US) 2015-09-08 US disclosed
US-20140371491-A1 DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES UNIGEN, INC. (US) 2014-12-18 US disclosed
US-8729136-B2 Diarylalkanes as potent inhibitors of binuclear enzymes UNIGEN, INC. (US) 2014-05-20 US disclosed
US-20130224135-A1 DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES UNIGEN, INC. (US) 2013-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130224135-A1 DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES TYR, DDT, HAAO MEN1 2314/4885KMT2A 2846/4885CYP3A4 223/4885
US-20160193126-A1 DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES TYR, DDT, HAAO MEN1 2314/4885KMT2A 2846/4885CYP3A4 223/4885
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B MEN1 3367/4885KMT2A 2792/4885CYP3A4 928/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 MEN1 2457/4885KMT2A 3188/4885CYP3A4 1589/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 MEN1 2457/4885KMT2A 3188/4885CYP3A4 1589/4885
US-20140371491-A1 DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES TYR, DDT, HAAO MEN1 2314/4885KMT2A 2846/4885CYP3A4 223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.